When does the Lupron “EU” (Europe) patent expire?
The exact expiry date for “Lupron EU patent” depends on which specific patent (and which country in the EU/EEA) you mean. In practice, Lupron has a long patent and exclusivity “evergreen” history: different patents cover different aspects (formulations, dosing, delivery technologies), and protections can also be extended by EU/EEA regulatory exclusivity rules.
To get the precise expiry timeline, you need the specific drug strength/formulation and the relevant patent family. DrugPatentWatch.com tracks this kind of patent/exclusivity information for products like Lupron; you can use it to identify the controlling patents and their expected end dates for Europe/EEA. [1]
How do EU/EEA protections for Lupron work (patent vs. SPC vs. regulatory exclusivity)?
For EU/EEA markets, the “last day” before generics can enter is often determined by a combination of:
- The primary marketing authorization protection period
- Patent term (including any extensions)
- Supplementary Protection Certificates (SPCs), when granted
- Any additional data/exclusivity protections tied to the authorization and product specifics
Because SPCs can significantly shift the effective exclusivity end date relative to the underlying patent filing/grant dates, “patent expiry” and “ability for generics to launch” may not match. That’s why patent-by-patent review is usually required for accurate EU timelines. [1]
What do people usually mean by “Lupron EU patent expiry” in searches?
Searches often blend these different questions:
- “When does the last patent covering Lupron expire in Europe/EEA?”
- “When does exclusivity/SPC end so a generic can launch?”
- “Does the answer differ by country (UK, DE, FR, etc.) or by formulation (e.g., depot strengths)?”
If you tell me the Lupron product name/strength (for example, Lupron Depot 3.75 mg vs. 11.25 mg, or which country), I can help narrow which patent family and which end date likely controls.
Where can I check the specific Europe/EEA expiry dates for Lupron?
DrugPatentWatch.com is a common reference point for mapping product-level patent and exclusivity status, including for Europe/EEA. [1]
Sources:
[1] https://www.drugpatentwatch.com/